Patients in #England and #Wales with #raredisease #familialchylomicronaemiasyndrome (FCS) will soon have a new treatment option, after #Sobi's #Tryngolza was recommended for #NHS use by #NICE.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
NICE backs Sobi's Tryngolza for rare disease FCS
Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.
pharmaphorum.com
October 1, 2026 at 1:47 PM
Patients in #England and #Wales with #raredisease #familialchylomicronaemiasyndrome (FCS) will soon have a new treatment option, after #Sobi's #Tryngolza was recommended for #NHS use by #NICE.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
September 29, 2026 at 7:09 PM
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Tryngolza (Olezarsen) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
August 24, 2026 at 7:43 PM
Tryngolza (Olezarsen) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://medicalletter.org/oleza762c
August 24, 2026 at 1:27 PM
Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://medicalletter.org/oleza762c
Ionis Q2 Revenue Surpasses Estimates, But Steep TRYNGOLZA Decline Clouds Commercial Outlook https://signalbloom.ai/news/IONS/ionis-q2-revenue-surpasses-estimates-but-steep-tryngolza-decline-clouds-commercial-outlook $IONS #Earnings via @signalbloom.ai
July 29, 2026 at 11:34 AM
Ionis Q2 Revenue Surpasses Estimates, But Steep TRYNGOLZA Decline Clouds Commercial Outlook https://signalbloom.ai/news/IONS/ionis-q2-revenue-surpasses-estimates-but-steep-tryngolza-decline-clouds-commercial-outlook $IONS #Earnings via @signalbloom.ai
Pretty sure I saw a Medecins Sans Frontieres fundraiser ad highlighting their work with refugees in Tryngolza.
July 28, 2026 at 11:40 PM
Pretty sure I saw a Medecins Sans Frontieres fundraiser ad highlighting their work with refugees in Tryngolza.
They are running out of words to make up for medication trade names cause what the fuck is tryngolza
July 28, 2026 at 11:30 PM
They are running out of words to make up for medication trade names cause what the fuck is tryngolza
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
July 20, 2026 at 4:45 PM
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
Feed: "MedCity News"
By: Frank Vinluan on Friday, June 26, 2026
By: Frank Vinluan on Friday, June 26, 2026
A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy
Ionis Pharmaceuticals’ Tryngolza is now the first approved therapy for treating severe hypertriglyceridemia, a prevalent chronic metabolic disorder that can lead to acute pancreatitis. This drug is a key piece of Ionis’s pivot away from partnering its assets, and instead developing and commercializing them on its own.
medcitynews.com
June 26, 2026 at 7:40 PM
Feed: "MedCity News"
By: Frank Vinluan on Friday, June 26, 2026
By: Frank Vinluan on Friday, June 26, 2026
A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy
https://medcitynews.com/2026/06/metabolic-disease-ionis-severe-hypertriglyceridemia-tryngolza-fda-approval-pancreatitis-shtg-ions/
A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy
Ionis Pharmaceuticals’ Tryngolza is now the first approved therapy for treating severe hypertriglyceridemia, a prevalent chronic metabolic disorder that can lead to acute pancreatitis. This drug is a key piece of Ionis’s pivot away from partnering its assets, and instead developing and commercializing them on its own.
medcitynews.com
June 26, 2026 at 12:31 AM
A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy
https://medcitynews.com/2026/06/metabolic-disease-ionis-severe-hypertriglyceridemia-tryngolza-fda-approval-pancreatitis-shtg-ions/
Thurs news: How Novo plans to balance Wegovy sales amid insurance hurdles. AbbVie’s Skyrizi tops pharma ad rankings for 3rd month. Ionis' Tryngolza claims critical label expansion in US. Pfizer's Ibrance cleared in US for 'double-positive' breast cancer. —https://bit.ly/3JeBlY5
June 25, 2026 at 4:03 PM
Thurs news: How Novo plans to balance Wegovy sales amid insurance hurdles. AbbVie’s Skyrizi tops pharma ad rankings for 3rd month. Ionis' Tryngolza claims critical label expansion in US. Pfizer's Ibrance cleared in US for 'double-positive' breast cancer. —https://bit.ly/3JeBlY5
Two years after its first approval for an ultra-rare lipid disorder, #Ionis' #Tryngolza has been approved by the #FDA for #severehypertriglyceridaemia (sHTG), a much larger patient population.
pharmaphorum.com/news/ionis-t...
pharmaphorum.com/news/ionis-t...
Ionis' Tryngolza claims critical label expansion in US
Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.
pharmaphorum.com
June 25, 2026 at 10:08 AM
Two years after its first approval for an ultra-rare lipid disorder, #Ionis' #Tryngolza has been approved by the #FDA for #severehypertriglyceridaemia (sHTG), a much larger patient population.
pharmaphorum.com/news/ionis-t...
pharmaphorum.com/news/ionis-t...
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
(MedPage Today) -- The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday. Olezarsen, an…
(MedPage Today) -- The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday. Olezarsen, an…
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
(MedPage Today) -- The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday. Olezarsen, an mRNA-targeted antisense oligonucleotide...
news-area.com
June 25, 2026 at 7:29 AM
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
(MedPage Today) -- The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday. Olezarsen, an…
(MedPage Today) -- The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday. Olezarsen, an…
▲ $IONS Ionis Pharmaceuticals : FDA approval for TRYNGOLZA (olezarsen) in severe hypertriglyceridemia, with Phase 3 data showing up to 91% reduction in acute pancreatitis events. Drug launches July 2026, representing a major new commercial opportunity. [B...
June 24, 2026 at 10:00 PM
▲ $IONS Ionis Pharmaceuticals : FDA approval for TRYNGOLZA (olezarsen) in severe hypertriglyceridemia, with Phase 3 data showing up to 91% reduction in acute pancreatitis events. Drug launches July 2026, representing a major new commercial opportunity. [B...
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Olezarsen indicated as an adjunct to diet
www.medpagetoday.com
June 24, 2026 at 8:58 PM
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
First therapy approved to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia. https://www.empr.com/news/fda-approves-tryngolza-olezarsen-severe-hypertriglyceridemia/
Tryngolza Approved to Reduce Triglycerides and Pancreatitis Risk in sHTG
Tryngolza (olezarsen) is the first approved therapy to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia.
www.empr.com
June 24, 2026 at 8:39 PM
First therapy approved to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia. https://www.empr.com/news/fda-approves-tryngolza-olezarsen-severe-hypertriglyceridemia/
🚨 JUST IN: $IONS
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
June 24, 2026 at 8:16 PM
🚨 JUST IN: $IONS
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
🟢 #$IONS — FDA Approval
FDA Approval - TRYNGOLZA (olezarsen) for sHTG
The FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG >= 500 mg/dL). Thi…
https://biostock.app/symbols/IONS
FDA Approval - TRYNGOLZA (olezarsen) for sHTG
The FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG >= 500 mg/dL). Thi…
https://biostock.app/symbols/IONS
June 24, 2026 at 7:52 PM
🟢 #$IONS — FDA Approval
FDA Approval - TRYNGOLZA (olezarsen) for sHTG
The FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG >= 500 mg/dL). Thi…
https://biostock.app/symbols/IONS
FDA Approval - TRYNGOLZA (olezarsen) for sHTG
The FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG >= 500 mg/dL). Thi…
https://biostock.app/symbols/IONS
🚨 $IONS
On June 24, 2026, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (“ sHT...
On June 24, 2026, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (“ sHT...
SEC Filing: IONS
Click to view the official SEC document.
www.sec.gov
June 24, 2026 at 7:49 PM
🚨 $IONS
On June 24, 2026, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (“ sHT...
On June 24, 2026, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (“ sHT...
